γδT cell therapy (Tri-Prime Gene Pharmaceutical)

N/A

Report date: 2025/09/10 16:17:38

Base Information

Drug NameγδT cell therapy (Tri-Prime Gene Pharmaceutical)

Drug Alias NameγδT细胞

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Gamma delta T-cell therapy

Mechanisms of ActionT lymphocyte replacements

TargetsNot applicable

Therapy Area/IndicationsSolid tumoursHematologic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaPhase 1 Clinical

Originator CompaniesBeijing Tri-Prime Gene Pharmaceutical Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesBeijing Tri-Prime Gene Pharmaceutical Co Ltd

Inactive CompaniesN/A

Active IndicationsSolid tumoursHematologic Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A